Spruce biosciences to participate in the guggenheim securities healthcare innovation conference

South san francisco, calif.--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today announced that javier szwarcberg, m.d., m.p.h., chief executive officer, will present at the guggenheim securities healthcare innovation conference on november 11, 2024, at 3:30 p.m. et. interested parties can access the live webca.
SPRB Ratings Summary
SPRB Quant Ranking